A Phase II, Open-label, Single-arm, Multi-cohort, Proof-of-principle Study to Investigate the Efficacy of Cobimetinib and Atezolizumab in Advanced Rare Tumors
Phase of Trial: Phase II
Latest Information Update: 29 May 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary)
- Indications Adenocarcinoma; Skin tumours; Squamous cell cancer
- Focus Proof of concept; Therapeutic Use
- 23 May 2019 Planned End Date changed from 1 Apr 2020 to 30 Apr 2020.
- 23 May 2019 Planned primary completion date changed from 1 Apr 2020 to 30 Apr 2020.
- 13 Apr 2017 New trial record